233 related articles for article (PubMed ID: 33714914)
1. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P; Parikh PK; Vyas VK; Ghate MD
Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS
Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of selective histone deacetylase 3 inhibition.
Zhang L; Chen Y; Jiang Q; Song W; Zhang L
Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
[TBL] [Abstract][Full Text] [Related]
4. Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment.
Elmezayen AD; Kemal Y
Comput Biol Chem; 2021 Jun; 92():107491. PubMed ID: 33930743
[TBL] [Abstract][Full Text] [Related]
5. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
Cao F; Zwinderman MRH; Dekker FJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
8. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron.
Kavianpour P; Gemmell MCM; Kahlert JU; Rendina LM
Chembiochem; 2020 Oct; 21(19):2786-2791. PubMed ID: 32367603
[TBL] [Abstract][Full Text] [Related]
10. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
12. An overview of naturally occurring histone deacetylase inhibitors.
Kim B; Hong J
Curr Top Med Chem; 2015; 14(24):2759-82. PubMed ID: 25487010
[TBL] [Abstract][Full Text] [Related]
13. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Adhikari N; Jha T; Ghosh B
J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
[TBL] [Abstract][Full Text] [Related]
14. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Jang YG; Hwang KA; Choi KC
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
Khadempar S; Lotfi M; Haghiralsadat F; Saidijam M; Ghasemi N; Afshar S
Comput Biol Med; 2023 Nov; 166():107518. PubMed ID: 37806058
[TBL] [Abstract][Full Text] [Related]
17. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
[TBL] [Abstract][Full Text] [Related]
18. Delineating binding potential, stability of Sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays.
Ganai SA; Srinivasan P; Rajamanikandan S; Shah BA; Mohan S; Gani M; Padder BA; Qadri RA; Bhat MA; Baba ZA; Yatoo MA
Chem Biol Drug Des; 2021 Sep; 98(3):363-376. PubMed ID: 33966346
[TBL] [Abstract][Full Text] [Related]
19. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
20. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
Spiegel S; Milstien S; Grant S
Oncogene; 2012 Feb; 31(5):537-51. PubMed ID: 21725353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]